Vinay Vanguru
YOU?
Author Swipe
View article: Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial Open
View article: Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.
Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia. Open
Aim: Richter transformation (RT) is an uncommon (2-10%) complication of chronic lymphocytic leukemia (CLL), most frequently manifesting as diffuse large B-cell lymphoma (RT-DLBCL, 90-95%). It is associated with complex genetic aberrations …
View article: Azer-cel, an allogeneic (allo) CD19 CAR T, in combination with low-dose interleukin-2 (IL-2) demonstrates clinical activity in patients with large B-cell lymphoma (LBCL) who relapsed after autologous (auto) CAR T
Azer-cel, an allogeneic (allo) CD19 CAR T, in combination with low-dose interleukin-2 (IL-2) demonstrates clinical activity in patients with large B-cell lymphoma (LBCL) who relapsed after autologous (auto) CAR T Open
Background: Relapse following auto CD19-directed CAR T-cell therapy remains a major challenge in LBCL as these patients (pts) have limited treatment options. Azer-cel is an allo, CD19-directed, CAR T-cell therapy derived from healthy donor…
View article: Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization
Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization Open
Introduction Up to 50% of patients with diffuse large B-cell lymphoma (DLBCL) relapse or are refractory to first-line therapy. Tisagenlecleucel, a CD19-directed chimeric antigen receptor (CAR)-T cell therapy, is approved for patients with …
View article: A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies
A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies Open
PCAB (prednisone, cyclophosphamide, doxorubicin, carmustine) is a single‐day regimen previously used for induction and now in relapsed/refractory multiple myeloma (RRMM). We retrospectively analysed the outcomes of 85 patients from five Au…
View article: Haemophagocytic lymphohistiocytosis secondary to disseminated histoplasmosis in an immunocompetent patient
Haemophagocytic lymphohistiocytosis secondary to disseminated histoplasmosis in an immunocompetent patient Open
Haemophagocytic lymphohistiocytosis secondary to Histoplasma infection is rare and almost always occurs in immunocompromised hosts. We report a 32-year-old immunocompetent man presenting with a nonspecific febrile illness found to h…
View article: Australasian Leukaemia & Lymphoma Group NHL35-Pacific: An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma - Trial in Progress
Australasian Leukaemia & Lymphoma Group NHL35-Pacific: An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma - Trial in Progress Open
Background: Primary Mediastinal B-cell Lymphoma (PMBL) comprises 10% of Diffuse large B-cell lymphoma (DLBCL), primarily affecting young adults. Combination chemoimmunotherapy with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and …
View article: Experimental and Clinical Pharmacology: Chimeric antigen receptor T-cell therapy
Experimental and Clinical Pharmacology: Chimeric antigen receptor T-cell therapy Open
Chimeric antigen receptor T-cell therapies are promising new options for patients with relapsed or refractory diffuse large B-cell lymphoma or acute lymphoblastic leukaemia. They increase complete response rates and the chances of achievin…
View article: PB2495: QUANTIFICATION AND IMMUNOPHENOTYPIC CHARACTERISATION OF CAR T-CELLS BY FLOW CYTOMETRY AND CORRELATION WITH CLINICAL OUTCOMES FOR PATIENTS WITH LARGE B CELL LYMPHOMA
PB2495: QUANTIFICATION AND IMMUNOPHENOTYPIC CHARACTERISATION OF CAR T-CELLS BY FLOW CYTOMETRY AND CORRELATION WITH CLINICAL OUTCOMES FOR PATIENTS WITH LARGE B CELL LYMPHOMA Open
Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical Background: Commercial autologous CD19 directed chimeric antigen receptor (CAR) T-cell therapy is an established therapy for relapsed/refractory large B-cell lympho…
View article: Red cell transfusion in alloimmunised allogeneic stem cell transplant patients
Red cell transfusion in alloimmunised allogeneic stem cell transplant patients Open
View article: Inverse relationship between oligoclonal expanded CD69− TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients
Inverse relationship between oligoclonal expanded CD69− TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients Open
CD8+CD57+ terminal effector T (TTE) cells are a component of marrow-infiltrating lymphocytes and may contribute to the altered immune responses in multiple myeloma (MM) patients. We analyzed TTE cells in the bone marrow (BM) and peripheral…
View article: Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report
Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report Open
View article: Detection and prognostic significance of mutations in the isocitrate dehydrogenase genes in myelodysplastic syndromes
Detection and prognostic significance of mutations in the isocitrate dehydrogenase genes in myelodysplastic syndromes Open